AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ATRC

Privitera Salvatore sold $408K of ATRC

Privitera Salvatore (Chief Technical Officer) sold 7,763 shares of AtriCure, Inc. (ATRC) at $52.50 ($0.41M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Privitera Salvatore
Published Sep 4, 2026, 11:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 11:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATRC
Neutral
high confidence
Mentioned
$ATRC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRCNeutralLow
01

Why it matters

The transaction represents a routine insider divestiture with limited market impact.

02

Market read

Low relevance; typical insider sale with minimal effect on stock.

03

What to watch

Potential upcoming corporate actions or dilution not indicated.

Relevance 3/10Novelty 4/10Timing: 2026-09-02 filing date

Background

Form 4 filings disclose insider transactions; this sale is part of a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$ATRCNeutralHigh confidence
Context

Chief Technical Officer sold 7,763 shares for $408K via a 10b5-1 plan on 2026-09-02.

Expected impact

No significant price impact expected.

Evidence & confidence

Sale size is small relative to float and disclosed via a routine Form 4.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues, but no pattern here.

Key entities

  • Company
    AtriCure, Inc.

    Medical device manufacturer listed on NASDAQ.

  • Individual
    Privitera Salvatore

    Chief Technical Officer of AtriCure.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATRC insider trading history →

Related articles

AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
JUL 23
$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi

SEC EDGAR 8-K3 min